Skip to content

Author

Shan-Yu Zhang

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Early prophylactic rituximab reduces EBV infection and PTLD in high-risk patients receiving allogeneic hematopoietic stem cell transplantation.

BACKGROUND Epstein-Barr virus (EBV) infection is a major complication after allogeneic hematopoietic cell transplantation (allo-HCT) and may progress to post-transplant lymphoproliferative disorder (PTLD). Current management relies on preemptive rituximab guided by EBV DNA monitoring, but this approach is inherently de...

Ao Zhang, Zi-Lu Zhang, Hao-Xing Bian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.